Welcome to our dedicated page for Royalty Pharma Plc news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma Plc stock.
Royalty Pharma plc (Nasdaq: RPRX) is a biopharmaceutical royalty company that frequently announces transactions, portfolio updates and financial results, making its news flow particularly relevant for investors following royalty-based business models in healthcare. Founded in 1996, the company describes itself as the largest buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry, with a portfolio of royalties on more than 35 commercial products and numerous development-stage therapies.
News about Royalty Pharma often centers on new royalty acquisitions and funding agreements. Recent press releases have described transactions such as acquiring remaining royalty interests in Roche’s Evrysdi, purchasing a royalty interest in Alnylam’s AMVUTTRA from Blackstone Life Sciences, and securing royalty interests in Nuvalent’s neladalkib and zidesamtinib. The company also reports synthetic royalty funding agreements, including a deal with Denali Therapeutics based on future net sales of tividenofusp alfa and a funding agreement with Teva for the anti-IL-15 antibody TEV-‘408 for vitiligo and celiac disease.
Royalty Pharma’s news feed additionally includes quarterly financial results, Portfolio Receipts updates, capital deployment figures, debt offerings, dividend declarations and participation in investor conferences. The company highlights clinical and regulatory milestones across its royalty portfolio, such as FDA approvals, Phase 3 trial initiations and pivotal data readouts for therapies like daraxonrasib, litifilimab, pelacarsen and other late-stage candidates.
Investors and observers who follow RPRX news can use these updates to track how the royalty portfolio is evolving, which therapeutic areas are gaining exposure, and how capital is being allocated across approved and investigational products. Regular news also provides insight into Royalty Pharma’s views on the royalty funding market, its use of non-GAAP liquidity measures, and its approach to shareholder returns through dividends and share repurchases.
Royalty Pharma (Nasdaq: RPRX) has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, before U.S. markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time on the same day.
Investors can access the conference call details and live webcast through the company's website at their Investors page. A replay of both the call and webcast will remain available on the website for a minimum of 30 days.
Royalty Pharma (RPRX) has appointed Dr. Vlad Coric to its Board of Directors, effective immediately. Dr. Coric, currently Chairman and CEO of Biohaven, brings over 20 years of drug discovery and clinical development experience from Yale School of Medicine and Bristol-Myers Squibb.
Under his leadership at Biohaven, Dr. Coric achieved significant milestones including:
- FDA approval and launch of Nurtec ODT for migraine treatment
- NDA filing for zavegepant, the first intranasal CGRP antagonist for migraine
- Led Biohaven's growth from founding through its $13 billion sale to Pfizer in May 2022
His expertise spans multiple therapeutic areas including neurology, psychiatry, immunology, virology, oncology and immuno-oncology. Dr. Coric completed his medical education at Wake Forest University and postdoctoral training at Yale School of Medicine.
Royalty Pharma (Nasdaq: RPRX) has announced plans to host an Investor Day on September 11, 2025, in New York City. The event will commence at 8:30 a.m. ET.
During the event, senior executives will present updates on the company's strategy for creating shareholder value by leveraging its distinctive business model and capabilities in the biopharma innovation funding market. The presentation will include interactive Q&A sessions.
Investors can access the live webcast through the 'Investors' section of Royalty Pharma's website, where it will remain archived for at least thirty days.
Royalty Pharma (Nasdaq: RPRX) has announced its upcoming participation in TD Cowen's 45th Annual Health Care Conference. The company will engage in a fireside chat scheduled for March 4, 2025, at 2:30 p.m. ET.
Interested parties can access the webcast through the company's 'Events' page on their investor relations website. The recording will remain available for a minimum of thirty days following the presentation.
Royalty Pharma (RPRX) has entered into an R&D funding agreement with Biogen, committing up to $250 million to support the development of litifilimab, a first-in-class investigational drug for lupus treatment. The funding will be provided over six quarters in exchange for regulatory milestones and mid-single digit royalties on worldwide sales.
Litifilimab is currently in Phase 3 trials for both systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), with results expected between 2026 and 2027. The drug has shown proof of concept and a generally well-tolerated safety profile in both conditions, with results published in the New England Journal of Medicine. SLE affects over 3 million patients worldwide, and litifilimab could potentially become the first targeted biologic specifically approved for CLE treatment.
Royalty Pharma (RPRX) reported strong financial results for Q4 and FY 2024, with Portfolio Receipts reaching $742 million in Q4 and $2,801 million for FY 2024. The company achieved 12% growth in Royalty Receipts in Q4 and 13% for FY 2024, driven by strong performance from products including Evrysdi, CF franchise, Trelegy, and Tremfya.
Key highlights include $2.8 billion in capital deployment in 2024, with royalties acquired on eight new therapies. The company provided 2025 guidance projecting Portfolio Receipts between $2,900-$3,050 million, representing 4-9% growth. Net cash from operations was $743 million in Q4 and $2,769 million for FY 2024.
In January 2025, RPRX announced a new $3 billion share repurchase program, with plans to repurchase $2 billion in 2025. The company also announced the acquisition of its external manager, expected to generate over $100 million in cash savings by 2026.
Royalty Pharma (RPRX) has completed the monetization of MorphoSys Development Funding Bonds, receiving $511 million in upfront cash. Combined with previous payments, this brings total proceeds to $530 million on their original $300 million investment made in September 2022.
The monetization was executed at a 5.35% discount rate, following Novartis' acquisition of MorphoSys. Prior to this transaction, RPRX received two quarterly payments of $9.7 million each in Q4 2024 and January 2025. The company plans to reinvest the proceeds into share repurchases and new royalty acquisitions as part of their updated capital allocation strategy.
The Development Funding Bonds were part of a larger 2021 strategic partnership where RPRX provided up to $2.025 billion for MorphoSys' acquisition of Constellation Pharmaceuticals, including royalties on Tremfya and other development-stage assets.
Royalty Pharma (Nasdaq: RPRX) has scheduled its fourth quarter and full year 2024 financial results announcement for Tuesday, February 11, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day. Investors can access the conference call details and live webcast through the company's website investor relations section. A replay of both the call and webcast will remain available on the website for a minimum of 30 days.
Royalty Pharma (RPRX) expects 2024 Portfolio Receipts of approximately $2.8 billion, reaching the upper end of guidance, driven by ~13% year-over-year growth in Royalty Receipts. The company deployed $2.8 billion in royalty transactions during 2024, including a record year for synthetic royalty deals at $925 million.
The company's development-stage pipeline, comprising over 40 projects, has the potential to generate peak royalties exceeding $1.2 billion annually. This is based on projected un-risk adjusted peak sales of over $21 billion for potential therapies in the late-stage pipeline.
In 2025, Royalty Pharma will benefit from several new product launches, including Voranigo, Yorvipath, Niktimvo, Rytelo, and Cobenfy. The company expects Adjusted EBITDA of $2,560-2,570 million and Portfolio Cash Flow of $2,450-2,455 million for full year 2024.
Royalty Pharma (RPRX) announced two major initiatives to enhance shareholder value: the acquisition of its external manager, RP Management, , and a new $3 billion share repurchase program. The internalization transaction will generate significant cash savings exceeding $100 million in 2026 and $175 million in 2030, with cumulative savings of over $1.6 billion over ten years.
The acquisition involves approximately 24.5 million shares of Royalty Pharma equity vesting over 5-9 years, $100 million in cash, and assuming $380 million of existing Manager debt. The total transaction value is approximately $1.1 billion. The company plans to repurchase $2 billion of shares in 2025, subject to market conditions.
The integration will simplify corporate structure, enhance governance, ensure management continuity, and increase economic returns on investments. Royalty Pharma maintains its commitment to mid-single digit annual dividend growth and investment grade credit rating.